Publications

2021

Morcos E, Falconer C, Grip ET, Geale K, Hellgren K, Poutakidis G, Altman D. “Association between surgical volumes and real-world healthcare cost when using a mesh capturing device for pelvic organ prolapse: A 5-years comparison between single- versus multicenter use.” Int Urogynecol J. (2021).

Söreskog, E., Lindberg, I., Kanis, J. et al. “Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden”. Osteoporos Int (2021).

Söreskog, E., Borgström, F., Lindberg, I. et al. “A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis.” Osteoporos Int (2021).

2020

Ortsäter, G., et al., “Incorporating the Environmental Impact into a Budget Impact Analysis: The Example of Adopting RESPIMAT((R)) Re-usable Inhaler.” Appl Health Econ Health Policy (2020).

Ortsäter, G., Geale, K., Dun, A.R. et al. “Clinical and Economic Burden of Pediatric Mild-to-Moderate Atopic Dermatitis: A Population-Based Nested Case–Control Study in Sweden.” Dermatol Ther (Heidelb).

Lindberg I, Lilja M, Geale K, Tian H, Richardson C, Scott A, Osmancevic A. “Incidence of Psoriatic Arthritis in Patients with Skin Psoriasis and Associated Risk Factors: A Retrospective Population-based Cohort Study in Swedish Routine Clinical Care.” Acta dermato-venereologica. 2020.

Rombach, I., Iftikhar, M., Jhuti, G.S. et al. (Gustavsson, A). “Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer’s disease scale: development and results from a mapping study.” Quality of Life Research.

Hansson-Hedblom, A., Axelsson, I., Jacobson, L., Tedroff, J., & Borgström, F. (2020). “Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway.” The journal of headache and pain, 21(1), 99.

Geale K, Henriksson M, Jokinen J, Schmitt-Egenolf M. “Association of Skin Psoriasis and Somatic Comorbidity With the Development of Psychiatric Illness in a Nationwide Swedish Study.” JAMA Dermatol. Published online June 03, 2020.

Kirk Geale, Ingrid Lindberg, Emma C Paulsson, E Christina M Wennerström, Anna Tjärnlund, Wim Noel, Dana Enkusson, Elke Theander. “Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden.” Rheumatology Advances in Practice. 2020.

Banefelt, J., Lindh, M., Svensson, M. K., Eliasson, B., & Tai, M. (2020). “Statin Dose Titration Patterns and Subsequent Major Cardiovascular Events in very High-Risk Patients – Estimates from Swedish Population-based Registry Data.” European heart journal. Quality of care & clinical outcomes , qcaa023.

Borgström, F., Karlsson, L., Ortsäter, G., Norton, N., Halbout, P., Cooper, C., Lorentzon, M., McCloskey, E. V., Harvey, N. C., Javaid, M. K., Kanis, J. A., & International Osteoporosis Foundation (2020). “Fragility fractures in Europe: burden, management and opportunities.” Archives of osteoporosis, 15(1), 59.

Gustavsson A, Pemberton-Ross P, Gomez Montero M, Hashim M, Thompson R. ”Challenges in demonstrating the value of disease-modifying therapies for Alzheimer’s disease.” Expert review of pharmacoeconomics & outcomes research. 2020.

Geale, K., H. Darabi, M. Lindh, H. Fues Wahl, O. Strom, H. Cao, L. Alvares, R. Dodge, E. Loefroth, A. Altraja, V. Backer, H. Backman, L. Bjermer, A. Bossios, B. Bogvald Aarli, B. Dahlen, O. Hilberg, C. Janson, H. Kankaanranta, J. Karjalainen, P. Kauppi, M. Kilpelainen, S. Lehmann, L. Lehtimaki, B. Lundback, T. Sandstrom, C. S. Ulrik, A. Sverrild, A. Viinanen, A. von Bulow, V. Yasinska and C. Porsbjerg (2020). “NORDSTAR: paving the way for a new era in asthma research.” Eur Respir J 55(4).

Janssen, O., S. J. B. Vos, G. Garcia-Negredo, C. Tochel, A. Gustavsson, M. Smith, A. Ly, M. Nelson, H. Baldwin, C. Sudlow, C. Bexelius, C. Jindra, N. Vaci, S. Bauermeister, J. Gallacher, A. Ponjoan, C. Dufouil, J. Garre Olmo, L. Pedersen, I. Skoog, A. Hottgenroth, P. J. Visser, J. van der Lei and C. Diaz (2020). “Real-world evidence in Alzheimer’s disease: The ROADMAP Data Cube.” Alzheimers Dement 16(3): 461-471.

Soreskog, E., F. Borgstrom, L. Shepstone, S. Clarke, C. Cooper, I. Harvey, N. C. Harvey, A. Howe, H. Johansson, T. Marshall, T. W. O’Neill, T. J. Peters, N. M. Redmond, D. Turner, R. Holland, E. McCloskey, J. A. Kanis and S. s. team (2020). “Long-term cost-effectiveness of screening for fracture risk in a UK primary care setting: the SCOOP study.” Osteoporos Int.

Soreskog, E., O. Strom, A. Spangeus, K. E. Akesson, F. Borgstrom, J. Banefelt, E. Toth, C. Libanati and M. Charokopou (2020). “Risk of major osteoporotic fracture after first, second and third fracture in Swedish women aged 50 years and older.” Bone 134: 115286.

Bauer, A., Wittenberg, R., Ly, A., Gustavsson, A., Bexelius, C., Tochel, C., . . . Sudlow, C. ”Valuing Alzheimer’s disease drugs: A health technology assessment perspective on outcomes.” International Journal of Technology Assessment in Health Care. 2020.

Strom, O., R. Lauppe, O. Ljunggren, A. Spangeus, G. Ortsater, J. O’Kelly and K. Akesson (2020). “Real-world effectiveness of osteoporosis treatment in the oldest old.” Osteoporos Int.

Landeiro, F., Mughal, S., Walsh, K., Nye, E., Morton, J., Williams, H., Ghinai, I., Castro, Y., Leal, J., Roberts, N., Wace, H., Handels, R., Lecomte, P., Gustavsson, A., Roncancio-Diaz, E., Belger, M., Jhuti, G. S., Bouvy, J. C., Potashman, M. H., Tockhorn-Heidenreich, A., … ROADMAP consortium (2020). ”Health-related quality of life in people with predementia Alzheimer’s disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review.” Alzheimer’s research & therapy. 2020.

Toth, E., J. Banefelt, K. Akesson, A. Spangeus, G. Ortsater and C. Libanati (2020). “History of Previous Fracture and Imminent Fracture Risk in Swedish Women Aged 55 to 90 Years Presenting With a Fragility Fracture.” J Bone Miner Res.

Widen, J., M. Ivarsson, L. Schalin, P. Vrouchou, M. Schwenkglenks, O. Heimburger, Z. Ademi and C. S. Sutherland (2020). “Cost-Effectiveness Analysis of Patiromer in Combination with Renin-Angiotensin-Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden.” Pharmacoeconomics.

2019

Green, C., R. Handels, A. Gustavsson, A. Wimo, B. Winblad, A. Skoldunger and L. Jonsson (2019). “Assessing cost-effectiveness of early intervention in Alzheimer’s disease: An open-source modeling framework.” Alzheimers Dement.

Hansson-Hedblom, A., E. Jonsson, P. Fritzell, O. Hagg and F. Borgstrom (2019). “The Association Between Patient Reported Outcomes of Spinal Surgery and Societal Costs: A Register Based Study.” Spine (Phila Pa 1976) 44(18): 1309-1317.

Iderberg H, Willers C, Borgstrom F, Hedlund R, Hagg O, Moller H, et al. “Predicting clinical outcome and length of sick leave after surgery for lumbar spinal stenosis in Sweden: a multi-register evaluation.” Eur Spine J. 2019;28(6):1423-32.

Kanis JA, Johansson H, Harvey NC, Lorentzon M, Liu E, Borgstrom F, et al. “Correspondence in response to OSIN-D-18-00831 quantifying imminent risk.” Osteoporos Int. 2019;30(2):525-6.

Ortsater G, Borgstrom F, Soulard S, Miltenburger C. A “Budget Impact Model to Estimate the Environmental Impact of Adopting RESPIMAT((R)) Re-usable in the Nordics and Benelux.” Adv Ther. 2019.

Tatangelo G, Watts J, Lim K, Connaughton C, Abimanyi-Ochom J, Borgstrom F, et al. “The Cost of Osteoporosis, Osteopenia, and Associated Fractures in Australia in 2017.” J Bone Miner Res. 2019;34(4):616-25.

Tochel C, Smith M, Baldwin H, Gustavsson A, Ly A, Bexelius C, et al. “What outcomes are important to patients with mild cognitive impairment or Alzheimer’s disease, their caregivers, and health-care professionals? A systematic review.” Alzheimers Dement (Amst).

Lauppe R, Akesson KE, Ljunggren O, Spangeus A, Ortsater G, Feudjo-Tepie M and Strom, O. Differing impact of clinical factors on the risk of fracture in younger and older women in the general population and an osteoporosis clinic population. Arch Osteoporos.

Lindh, M., J. Banefelt, K-M. Fox, S. Hallberg, M-H. Tai, M. Eriksson, G. Villa, M-K. Svensson, and Y. Qian (2019). “Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population–estimates from Swedish population-based register data.” European Heart Journal – Quality of Care and Clinical Outcomes.

Grip, E. T., Svensson, A. M., Miftaraj, M., Eliasson, B., Franzén, S., Gudbjörnsdottir, S., & Carlsson, K. S. (2019). Real-World Costs of Continuous Insulin Pump Therapy and Multiple Daily Injections for Type 1 Diabetes: A Population-Based and Propensity-Matched Cohort From the Swedish National Diabetes Register. Diabetes care, 42(4), 545-552.

Banefelt, J., K-E. Åkesson, A. Spångéus, O. Ljunggren, L. Karlsson, O. Ström, G. Ortsäter, C. Libanati, and E. Toth (2019). “Risk of imminent fracture following a previous fracture in a Swedish database study.” Osteoporosis International.

2018

Rudberg, A-S., E. Berge, A. Gustavsson, P. Näsman, and E. Lundström (2018). “Long-term health-related quality of life, survival and costs by different levels of functional outcome six months after stroke.” European Stroke Journal.

Guirant, L., F. Carlos, D. Curiel, J. A. Kanis, F. Borgstrom, A. Svedbom and P. Clark (2018). “Health-related quality of life during the first year after a hip fracture: results of the Mexican arm of the International Cost and Utility Related to Osteoporotic Fractures Study (MexICUROS).” Osteoporos Int 29(5): 1147-1154.

Hansson-Hedblom, A., C. Almond, F. Borgstrom, I. Sly, D. Enkusson, A. Troelsgaard Buchholt and L. Karlsson (2018). “Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden.” Cost Eff Resour Alloc 16: 28.

Jonsson, E., A. Hansson-Hedblom, O. Ljunggren, K. Akesson, A. Spangeus, J. A. Kanis and F. Borgstrom (2018). “A health economic simulation model for the clinical management of osteoporosis.” Osteoporos Int 29(3): 545-555.

Kanis, J. A., H. Johansson, A. Oden, N. C. Harvey, V. Gudnason, K. M. Sanders, G. Sigurdsson, K. Siggeirsdottir, L. A. Fitzpatrick, F. Borgstrom and E. V. McCloskey (2018). “Characteristics of recurrent fractures.” Osteoporos Int 29(8): 1747-1757.

Luthman, S., J. Widen and F. Borgstrom (2018). “Appropriateness criteria for treatment of osteoporotic vertebral compression fractures.” Osteoporos Int 29(4): 793-804.

Olafsson, G., E. Jonsson, P. Fritzell, O. Hagg and F. Borgstrom (2018). “Cost of low back pain: results from a national register study in Sweden.” Eur Spine J.

Svedbom, A., F. Borgstrom, E. Hernlund, O. Strom, V. Alekna, M. L. Bianchi, P. Clark, M. D. Curiel, H. P. Dimai, M. Jurisson, A. Uuskula, M. Lember, R. Kallikorm, O. Lesnyak, E. McCloskey, O. Ershova, K. M. Sanders, S. Silverman, M. Tamulaitiene, T. Thomas, A. N. A. Tosteson, B. Jonsson and J. A. Kanis (2018). “Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS.” Qual Life Res 27(3): 707-716.

2017

Eriksson, D., L. Karlsson, O. Eklund, H. Dieperink, E. Honkanen, J. Melin, K. Selvig and J. Lundberg (2017). “Real-world costs of autosomal dominant polycystic kidney disease in the Nordics.” BMC Health Serv Res 17(1): 560.

Gustavsson, A., C. Green, R. W. Jones, H. Forstl, D. Simsek, F. de Reydet de Vulpillieres, S. Luthman, N. Adlard, S. Bhattacharyya and A. Wimo (2017). “Current issues and future research priorities for health economic modelling across the full continuum of Alzheimer’s disease.” Alzheimers Dement 13(3): 312-321.

Jonsson, E., G. Olafsson, P. Fritzell, O. Hagg and F. Borgstrom (2017). “Profile of Low Back Pain: Treatment and Costs Associated With Patients Referred to Orthopaedic Specialists in Sweden.” Spine (Phila Pa 1976).

Karlsson, L., J. Mesterton, M. F. Tepie, M. Intorcia, J. Overbeek and O. Strom (2017). “Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control.” Arch Osteoporos 12(1): 81.